Abigail Colley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abigail Colley has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ann E. Sluder
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, United States
1 shared publication - Daiki Sugita
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication - George Steinfels
Voltron Therapeutics, Inc., New York, New York
1 shared publication - Ishan Capila
Voltron Therapeutics, Inc., New York, New York
1 shared publication - Jacob J. Smith
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication - James Adeosun
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF19
New Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice
Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal endotoxin. Assembled VTX-067 is designed to elicit both CD4+ and CD8+ T-cell responses against HPV-associated tumors. In multiple tumor models expressing HPV E6/E7, intradermal vaccination with VTX-067 induced potent and dose-dependent HPV E6/E7–specific CD8+ and CD4+ T-cell responses without evidence of local reactogenicity. Therapeutic vaccination significantly delayed subcutaneous tumor progression, extended survival, and provided durable protection against tumor rechallenge. VTX-067 treatment increased intratumoral CD8+ T-cell infiltration, elevated the CD8:regulatory T-cell ratio, and upregulated a Th1/cytotoxic transcriptional program, including Ifnγ, Tbx21, Stat1, and granzyme B. Depletion of CD8+ T cells eliminated vaccine efficacy, whereas adoptive transfer of VTX-067–primed CD8+ T cells conferred tumor protection in recipient mice. In a cervicovaginal orthotopic model, both intradermal and intramucosal administration generated systemic E6/E7-specific effector responses and sustained control of mucosal tumors. Notably, combining a suboptimal VTX-067 dose with the immunomodulatory agent lenalidomide further enhanced tumor control and survival, demonstrating a potential dose-sparing strategy. These findings establish VTX-067 as a safe, highly immunogenic therapeutic vaccine with CD8+ T cell–dependent antitumor activity and support its clinical development alone or in combination with immune-modulating agents for HPV-associated cancers.
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF19
Open AccessNew Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice
Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal endotoxin. Assembled VTX-067 is designed to elicit both CD4+ and CD8+ T-cell responses against HPV-associated tumors. In multiple tumor models expressing HPV E6/E7, intradermal vaccination with VTX-067 induced potent and dose-dependent HPV E6/E7–specific CD8+ and CD4+ T-cell responses without evidence of local reactogenicity. Therapeutic vaccination significantly delayed subcutaneous tumor progression, extended survival, and provided durable protection against tumor rechallenge. VTX-067 treatment increased intratumoral CD8+ T-cell infiltration, elevated the CD8:regulatory T-cell ratio, and upregulated a Th1/cytotoxic transcriptional program, including Ifnγ, Tbx21, Stat1, and granzyme B. Depletion of CD8+ T cells eliminated vaccine efficacy, whereas adoptive transfer of VTX-067–primed CD8+ T cells conferred tumor protection in recipient mice. In a cervicovaginal orthotopic model, both intradermal and intramucosal administration generated systemic E6/E7-specific effector responses and sustained control of mucosal tumors. Notably, combining a suboptimal VTX-067 dose with the immunomodulatory agent lenalidomide further enhanced tumor control and survival, demonstrating a potential dose-sparing strategy. These findings establish VTX-067 as a safe, highly immunogenic therapeutic vaccine with CD8+ T cell–dependent antitumor activity and support its clinical development alone or in combination with immune-modulating agents for HPV-associated cancers.